Glass House Brands (GLAS) Asset Writedowns and Impairment (2022 - 2026)
Glass House Brands' (GLAS) quarterly Asset Writedowns and Impairment came in at -$128000.0 in Q1 2026, up 76.68% on a QoQ basis from -$549000.0 in Q4 2025.
Glass House Brands (GLAS) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 5 years of Asset Writedowns and Impairment data on file, last reported at -$128000.0 in Q1 2026.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to -$128000.0 in Q1 2026; TTM through Mar 2026 was -$522000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $1.4 million, down 78.56% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at -$128000.0, up from -$549000.0 in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for GLAS reached as high as $1328.4 billion in Q2 2023 and fell as low as -$549000.0 in Q4 2025.
- Historically, Asset Writedowns and Impairment has averaged $132.8 billion across 5 years, with a median of $157541.0 in 2022.
- Across the five-year window, Asset Writedowns and Impairment jumped 436751488.8% in 2023 and slumped 100.18% in 2024, its largest moves.
- Year by year, Asset Writedowns and Impairment stood at $817875.0 in 2022, then surged by 162424231.35% to $1328.4 billion in 2023, then plunged by 100.0% to $155000.0 in 2024, then slumped by 454.19% to -$549000.0 in 2025, then jumped by 76.68% to -$128000.0 in 2026.
- Per Business Quant data, the three most recent Asset Writedowns and Impairment figures were -$128000.0 in Q1 2026, -$549000.0 in Q4 2025, and $155000.0 in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -128,000.00 |
| Mar 31, 2026 | -128,000.00 |
| Dec 31, 2025 | -549,000.00 |
| Dec 31, 2025 | -549,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Jun 30, 2024 | 155,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Jun 30, 2023 | 1,328.43 Bn |
| Jun 30, 2023 | 1,328.43 Bn |
| Mar 31, 2023 | 5.53 Mn |
| Mar 31, 2023 | 5.53 Mn |
| Dec 31, 2022 | 817,875.00 |
| Dec 31, 2022 | 817,875.00 |
| Sep 30, 2022 | 160,082.00 |
| Sep 30, 2022 | 160,082.00 |
| Jun 30, 2022 | 304,161.00 |
| Jun 30, 2022 | 304,161.00 |
| Mar 31, 2022 | 80,110.00 |
| Mar 31, 2022 | 80,110.00 |